Chronische Inflammation und Biomarker

Ist Altern ein Ausdruck von chronischer Entzündung?
Beiträge zum Themenschwerpunkt

Zusammenfassung

Altern unterliegt einer hohen inter- und intraindividuellen Variation. Subklinische und manifeste kardiovaskuläre Erkrankungen beschleunigen den Alterungsprozess des Organismus in einzelnen Komponenten und insgesamt. Daraus wurde gefolgert, dass chronische Inflammation ein ursächliches Modell für den Alterungsprozess darstellt, und der Begriff „inflammageing“ geprägt. Verschiedene Biomarker (C-reaktives Protein, Interleukin 6, Tumor-Nekrose-Faktor α, Fibrinogen, Albumin und Serumamyloid A) wurden in diesem Zusammenhang beschrieben. Diese Biomarker stehen im Kontext mit den Veränderungen des Immunsystems über die Lebenszeit (Immunseneszenz), viral induzierten Prozessen, dem vermehrten Auftreten von Markern für oxidativen Stress und genetischen Veränderungen. Zum jetzigen Zeitpunkt ist die Anwendung solcher Marker als Kennzeichnung für den Status des Alterungsprozesses und hinsichtlich der prognostischen Aussagekraft im mittel- und längerfristigen Zeitspektrum noch nicht zu empfehlen. Ob „inflammageing“ ein eigenständiges Modell für die Beschreibung des Alterungsprozess oder sekundärer Ausdruck anderer Mechanismen ist, bleibt Gegenstand der Diskussion.

Schlüsselwörter

Biomarker Ältere Menschen Biologisches Altern Inflammation Gerontologie 

Chronic inflammation and biomarkers

Is ageing an expression of chronic inflammation?

Abstract

Ageing shows a high interindividual and intraindividual variability. Subclinical and clinical cardiovascular diseases accelerate the ageing process in part and in total. This leads to the idea that ageing is a result of a chronic inflammation process and to the term “inflammageing”. A variety of biomarkers (e.g. C-reactive protein, interleukin-6, tumor necrosis factor alpha, fibrinogen, albumin and serum amyloid A) are described in this context. Furthermore there is a relationship to changes in the immune system across the lifespan (immunosenescence), viral infections, the occurrence of markers of oxidative stress and genetic changes. At this point in time the role for determining ageing and its use as a prognostic tool seems to be impossible. Whether inflammageing is a valid model for describing the ageing process or is the consequence of other mechanisms needs further discussion.

Keywords

Biologic markers Elderly Biological aging Inflammation Gerontology 

Literatur

  1. 1.
    Rosamond W, Flegal K, Furie K et al (2008) Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117:e25–e146PubMedCrossRefGoogle Scholar
  2. 2.
    Robert-Koch-Institut (2009) Gesundheit und Krankheit im Alter. Beiträge zur Gesundheitsberichterstattung des Bundes. RKI, BerlinGoogle Scholar
  3. 3.
    Dam RM van, Spiegelman D, Franco OH, Hu FB (2008) Combined impact of lifestyle factors on mortality: prospective cohort study in US women. BMJ 337:a1440PubMedCrossRefGoogle Scholar
  4. 4.
    Newman AB, Arnold AM, Naydeck BL et al (2003) „Successfull aging“: effect of subclinical cardiovascular disease. Arch Intern Med 163:2315–2322PubMedCrossRefGoogle Scholar
  5. 5.
    Fried L, Kronmal RA, Newman AB et al (1998) Risk factors for 5-year mortality in older adults. The Cardiovascular Health Study. JAMA 279:585–592PubMedCrossRefGoogle Scholar
  6. 6.
    Khaw K-T, Wareham N, Bingham S et al (2008) Combined impact of health behaviours and mortality in men and women: The EPIC-Norfolk Prospective Population Study. PLoS Med 5:e12PubMedCrossRefGoogle Scholar
  7. 7.
    Dolan H, Crain B, Troncoso J et al (2010) Arteriosclerosis, dementia, and Alzheimer’s disease in the BLSA cohort. Ann Neurol 68:231–240PubMedGoogle Scholar
  8. 8.
    Beach TG, Maarouf CL, Brooks RG et al (2011) Reduced clinical and postmortem measures of cardiac pathology in subjects with advanced Alzheimer’s disease. BMC Geriatr 11:3PubMedCrossRefGoogle Scholar
  9. 9.
    Flicker L (2010) Cardiovascular risk factors, cerebrovascular disease burden, and healthy brain aging. Clin Geriatr Med 26:17–27PubMedCrossRefGoogle Scholar
  10. 10.
    Fillit H, Nash DT, Rundek T, Zuckerman A (2008) Cardiovascular risk factors and dementia. Am J Geriatr Pharmacother 6:100–118PubMedCrossRefGoogle Scholar
  11. 11.
    Middleton LE, Yaffe K (2009) Promising strategies for the prevention of dementia. Arch Neurol 66:1210–1215PubMedCrossRefGoogle Scholar
  12. 12.
    Middleton LE, Yaffe K (2010) Targets for the prevention of dementia. J Alzheimers Dis 20:915–924PubMedGoogle Scholar
  13. 13.
    Willett WC (2002) Balancing life-style and genomics research for disease prevention. Science 296:695–698PubMedCrossRefGoogle Scholar
  14. 14.
    Forman JP, Stampfer MJ, Curhan GC (2009) Diet and lifestyle risk factors associated with incident hypertension in women. JAMA 302: 401–411PubMedCrossRefGoogle Scholar
  15. 15.
    Knopman DS, Roberts R (2010) Vascular risk factors: imaging and neuropathologic correlates. J Alzheimer Dis 20:699–709Google Scholar
  16. 16.
    Zethelius B, Berglund L, Sundström J et al (2008) Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358:2107–2116PubMedCrossRefGoogle Scholar
  17. 17.
    Melander O, Newton-Cheh C, Almgren P et al (2009) Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 302:49–57PubMedCrossRefGoogle Scholar
  18. 18.
    Zacho J, Tybjaerg-Hansen A, Jensen JS et al (2008) Genetically elevated c-reactive protein and ischemic vascular disease. N Engl J Med 359:1897–1908PubMedCrossRefGoogle Scholar
  19. 19.
    Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 359:2195–2207PubMedCrossRefGoogle Scholar
  20. 20.
    Gurven M, Kaplan H, Winking J et al (2009) Inflammation and infection do not promote arterial aging and cardiovascular disease risk factors among lean horticulturalists. PLoS One 4:e6590PubMedCrossRefGoogle Scholar
  21. 21.
    Helfand M, Buckley DL, Freeman M et al (2009) Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the US Preventive Services Task Force. Ann Intern Med 151:496–507PubMedGoogle Scholar
  22. 22.
    Wang TJ (2011) Usefulness of novel screening tests for cardiovascular disease. Arch Intern Med 171:284–285PubMedCrossRefGoogle Scholar
  23. 23.
    Wald NJ, Morris JK (2011) Assessing risk factors as potential screening tests. A simple assessment tool. Arch Intern Med 171:286–291PubMedCrossRefGoogle Scholar
  24. 24.
    The Emerging Risk Factors Collaboration (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375:132–140CrossRefGoogle Scholar
  25. 25.
    C-Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC) (2011) Association between C-reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ 342:d548CrossRefGoogle Scholar
  26. 26.
    De Martinis M, Franceschi C, Monti D, Ginalsi L (2006) Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol 80:219–227CrossRefGoogle Scholar
  27. 27.
    Gruenewald TL, Seeman TE, Ryff CD et al (2006) Combinations of biomarkers predictive of later life mortality. Proc Natl Acad Sci USA 103:14158–14163PubMedCrossRefGoogle Scholar
  28. 28.
    Melander O, Newton-Cheh C, Almgren P et al (2009) Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 302:49–57PubMedCrossRefGoogle Scholar
  29. 29.
    Crimmins E, Vasunilashorn S, Kim JK, Alley D (2008) Biomarkers related to aging in human populations. Adv Clin Chem 46:161–216PubMedCrossRefGoogle Scholar
  30. 30.
    Giunta S (2006) Is inflammaging an auto(innate)immunity subclinical syndrome? Immun Ageing 3:12PubMedCrossRefGoogle Scholar
  31. 31.
    Huang H, Patel DD, Manton KG (2005) The immune system in aging: roles of cytokines, T cells and NK cells. Front Biosci 10:192–215PubMedCrossRefGoogle Scholar
  32. 32.
    Müller-Werdan U (2007) Inflammation and Ageing. Z Gerontol Geriatr 40:362–365PubMedCrossRefGoogle Scholar
  33. 33.
    Licastro F, Candore G, Lio D et al (2005) Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing:1–14Google Scholar
  34. 34.
    Ridker PM (2007) Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications of longevity. Nutr Rev 65:253–259CrossRefGoogle Scholar
  35. 35.
    Johnson TE (2006) Recent results: biomarkers of aging. Exp Gerontol 41:1243–1246PubMedCrossRefGoogle Scholar
  36. 36.
    Rattan SIS (2008) Increased molecular damage and heterogeneity as the basis of aging. Biol Chem 389:267–272PubMedCrossRefGoogle Scholar
  37. 37.
    Franceschi C, Olivieri F, Marchegiani F et al (2005) Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mech Ageing Dev 126:351–361PubMedCrossRefGoogle Scholar
  38. 38.
    Vaupel JW (2010) Biodemography of human ageing. Nature 464:536–542PubMedCrossRefGoogle Scholar
  39. 39.
    Sahin E, DePinho R (2010) Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 464:520–528PubMedCrossRefGoogle Scholar
  40. 40.
    Kenyon CJ (2010) The genetics of ageing. Nature 464:504–512PubMedCrossRefGoogle Scholar
  41. 41.
    Knopman DS, Roberts R (2010) Vascular risk factors: imaging and neuropathologic correlates. J Alzheimer Dis 20:699–709Google Scholar
  42. 42.
    Savva GM, Stephan BCM; the Alzheimer’s Society Vascular Dementia Systematic Review Group (2010) Epidemiological studies of the effect of stroke on incident dementia: a systematic review. Stroke 41:e41–e46PubMedCrossRefGoogle Scholar
  43. 43.
    Kwok CS, Loke YK, Hale R et al (2011) Atrial fibrillation and incidence of dementia. A systematic review and meta-analysis. Neurology 76:914–921PubMedCrossRefGoogle Scholar
  44. 44.
    Peters R, Poulter R, Beckett N et al (2009) Cardiovascular and biochemical risk factors for incident dementia in the hypertension in the very elderly trial. J Hypertens 27:2055–2062PubMedCrossRefGoogle Scholar
  45. 45.
    McGuinnes B, Todd S, Passmore P, Bullock R (2009) Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev 7:CD004034Google Scholar
  46. 46.
    Sanz C, Andrieu S, Sinclair A et al; REAL.FR Study Group (2009) Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology 73:1359–1366PubMedCrossRefGoogle Scholar
  47. 47.
    Tan ZS, Seshadri S, Beiser A et al (2003) Plasma total cholesterol level as a risk factor for Alzheimer disease. Arch Intern Med 163:1053–1057PubMedCrossRefGoogle Scholar
  48. 48.
    Rea TD, Breitner JC, Psyta BM et al (2005) Statin use and the risk of incident dementia. Arch Neurol 62:1047–1051PubMedCrossRefGoogle Scholar
  49. 49.
    McGuinnes B, Craig D, Bullock R, Passmore P (2009) Statins for the prevention of dementia. Cochrane Database Syst Rev 2:CD003160Google Scholar
  50. 50.
    Plassman BL, Williams JW, Burke JR et al (2010) Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life. Ann Intern Med 153:182–193PubMedGoogle Scholar
  51. 51.
    Daviglus ML, Bell CC, Berrettini W et al (2010) National Institutes of Health State-of-the-Science conference statement: preventing Alzheimer disease and cognitive decline. Ann Intern Med 153:176–181PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Klinik für GeriatrieKrankenhaus LindenbrunnCoppenbrüggeDeutschland
  2. 2.Klinik für GeriatrieUniversitätsklinikum JenaJenaDeutschland

Personalised recommendations